Aier released its 2019 semi-annual report_ the market value exceeded 100 billion, and the revenue of optometry services

Aier released its 2019 semi-annual report: the market value exceeded 100 billion, and the revenue of optometry services increased by more than 30%

On the eve of the 10th anniversary of its listing, the market value of Aier Ophthalmology, a leading chain hospital, reached a new high of 101.7 billion yuan, handing over a sustained and high-growth interim report, once again proving its "white horse" quality. On the evening of August 22, Aier Ophthalmology disclosed its 2019 semi-annual report. In the first half of the year, the company's revenue and net profit continued to maintain steady growth, and on the basis of a high base in the same period last year, the operating income was 4.749 billion yuan, a year-on-year increase of 25.64%; the net profit was 731 million yuan, a year-on-year increase of 33.6%; The net profit after deducting non-profits was 695 million yuan, a year-on-year increase of 31.93%. Ten years of high growth, the main business has continued to grow, Chen Bang, chairman of Aier Ophthalmology, said that standing in the first year of the "second venture", Aier Ophthalmology will continue to accelerate the layout of the medical network and continuously improve multi-level medical services around the strategic goal of building an "eye health ecosystem"; Comprehensively consolidate the foundation for development, integrate, share and optimize the allocation of regional resources; Innovate talent training methods, promote the emergence of high-level scientific research achievements, and steadily enhance the company's core competitiveness. The semi-annual report shows that the business of Aier Ophthalmology has grown rapidly. In the first half of the year, the company's optometry service revenue increased by more than 30%, and the gross profit margin was as high as 53.06%, accounting for 17.65% of the total revenue; The revenue of refractive surgery, anterior segment surgery, and posterior segment surgery also maintained a growth rate of about 20%. Chen Bang (right), chairman of Aier Ophthalmology, and Li Li, president of Aier Ophthalmology, mentioned that the transformation and upgrading of the company's cataract business has shown results, with the "gold content" rising steadily, and the gross profit margin reaching 39.35%, an increase of 1.89% over the same period last year. Li Li, president of Aier Ophthalmology, said that during the period of medical insurance, the outpatient volume and surgery volume of low-end cataract have been affected to a certain extent, but China has entered an aging society, and there are more and more patients with cataract for a long time. The company has formed a pattern of multidisciplinary coordinated development, and the "chassis" is stable, and the "curve" of cataract is the time for "overtaking". During the reporting period, the company's hierarchical chain system was further improved, and multi-level ophthalmic medical services were gradually implemented. The company has acquired or built 13 hospitals and 9 outpatient departments or clinics, including Xiangtan Renhe and Pu'er Aier, including Chongqing Aier Children's Eye Hospital, which focuses on children's and adolescent eye diseases, and Shenyang Aier Excellence Eye Hospital, which focuses on the high-end medical service market. In the first half of the year, the company established a hierarchical diagnosis and treatment platform for difficult fundus diseases, ranking first in China, covering 30 provinces and municipalities. While accelerating the construction of a medical network system, Aier Ophthalmology actively integrates with the international industrial ecology and promotes the clinical transformation and innovation of ophthalmology and vision science. During the reporting period, the company's science, education and research system has become more and more perfect, and high-level scientific research achievements have been emerging, with a total of 128 papers published in various journals and 42 scientific research projects approved. As a "new business card" of the medical industry in Hunan Province, Aier Ophthalmology's construction of an eye health ecosystem has also received strong support from the local government. The government work report of the Changsha Municipal People's Government pointed out: "support the development of Aier Ophthalmology and build the capital of the 'eye health' industry". As of the close of trading on August 22, the market value of Aier Ophthalmology reached 101.7 billion yuan, ranking first in Hunan stocks. Compared with 6.9 billion yuan at the beginning of its listing in October 2009, the company's market value has increased by nearly 13.7 times. Behind the rising market value is the solid performance of Aier Ophthalmology, driven by epitaxy and endogenous. In the past ten years, the compound growth rate of the company's operating income and net profit has exceeded 30%, and the image of "White Horse Stock" has been deeply rooted in the hearts of the people. Although the performance and market value are flying together, Chen Bang is very sober that the company's management will never sit back and relax. The next ten years will be a period of upgrading and shifting from bigger to stronger, and a period of coordinated development of quantitative growth and quality improvement. The company's management will continue to improve the benchmarking of the group and hospitals at all levels, and maintain a good sense of innovation and enterprising state. As one of the representative targets of value investment in the capital market, Aier Ophthalmology insists on paying dividends every year, and up to now, the cumulative cash dividends and bonus shares are 1.788 billion yuan, which has exceeded the total amount of funds raised in its IPO. Recently, Aier Ophthalmology distributed special "benefits" to long-term old shareholders: Chen Bang, chairman of the two founders, and Li Li, president of the company, plan to give 100 shares of Aier Ophthalmology stock income coupons to individual investors who meet the conditions of "600 shares in 6 years", and the recipients can submit an exchange request on October 30 (the anniversary date of listing) in any future year, and the two founders will exchange the equivalent cash. This innovative initiative has aroused widespread public attention and enthusiastic response from investors. If the closing price of Aier Ophthalmology on August 22 is 32.82 yuan per share, the "additional dividend" of each "Lao Tie" shareholder will be as high as 3,282 yuan. Wu Shijun, secretary of the board of directors of Aier Ophthalmology, said that nearly 200 investor stock trading orders have been received, and many are still on the way. Chen Bang said that although the existing database cannot query the number of eligible investors for the time being, as long as the conditions are met, there is no cap, and as many people as there are cashed out. In the first half of 2019, the company continued to focus on the strategic goal of building an "eye health ecosystem", responded to the development opportunities and challenges of the industry with the spirit of "second entrepreneurship", consolidated the foundation for development, improved multi-level medical services, gathered high-end talents in the industry, improved scientific research and academic capabilities, helped the prevention and control of myopia in adolescents in the country, enhanced brand influence, and the company's operating performance continued to maintain steady growth.During the reporting period, the company achieved 3,164,300 outpatient visits on the basis of a high base in the same period of the previous year, a year-on-year increase of 15.31%; the number of surgeries was 299,600, a year-on-year increase of 7.02%; the operating income was 4748.9118 million yuan, a year-on-year increase of 25.64%; The operating profit was 1034.4684 million yuan, a year-on-year increase of 34.33%; the net profit was 731.0872 million yuan, a year-on-year increase of 33.60%; The net profit attributable to the parent company was 695.0178 million yuan, a year-on-year increase of 36.53%. The net profit attributable to the parent company after deducting non-recurring gains and losses was 695.042 million yuan, a year-on-year increase of 31.93%. 1. Continue to accelerate the layout of the medical network and continuously improve the multi-level medical servicesDuring the reporting period, the company continued to accelerate the layout of the medical network, continuously improved the regional and intra-city hierarchical chain system in the province, expanded the network coverage, and gradually implemented multi-level ophthalmic medical services. First, in terms of medical network layout, the company has acquired or newly built 13 hospitals and 9 outpatient departments or clinics, including Xiangtan Renhe, Pu'er Aier, Zibo Kangming Aier, and Shanghai Aier Jingliang. Second, in terms of deepening the segmentation of medical services, the company acquired Chongqing Aier Children's Eye Hospital, which focuses on the prevention, diagnosis and treatment, popularization of science and research of various childhood and adolescent eye diseases and congenital hereditary eye diseases. Third, in terms of high-end medical care, Shenyang Aier Excellence Eye Hospital opened, bringing together more experts and famous doctors, providing international standard diagnosis and treatment services for high-end customers in China and Northeast Asia, and increasing efforts to develop the high-end medical service market. 2. Intensify the integration of resources and vigorously promote the construction of the eye health ecosystemDuring the reporting period, the company increased the integration of resources and promoted the construction of the eye health ecosystem with the help of the advantages of the international platform and the huge medical network system. The company cooperated to invest in the establishment of Hunan Meiou Medical Technology Co., Ltd. to steadily extend and expand the industrial chain. At the same time, the company signed a strategic cooperation agreement with Huawei and Topway Information, and the three parties will cooperate in cloud computing, big data, and enterprise digital transformation. In addition, the company actively integrates with the international industrial ecology and promotes the clinical transformation and innovation of ophthalmology and vision science. The company, together with the Ophthalmology and Vision Science Committee of the Chinese Research Hospital Association, the Singapore Eye Research Institute, and the Remengxi International Vision Science Foundation, co-hosted the first China International Ophthalmology and Vision Science Transformation and Innovation Forum, and officially launched the "Aier-Remengxi Vision Science Incubator", which is expected to enhance the clinical transformation and independent innovation capabilities of ophthalmic science and technology. The company's strategic goal of building an eye health ecosystem has received strong support from local governments. The government work report of the Changsha Municipal People's Government pointed out: "support the development of Aier Ophthalmology and build the capital of the 'eye health' industry". 3. Comprehensively consolidate the foundation for development and empower the rapid development of hospitalsDuring the reporting period, the company further consolidated the foundation for development, expanded and strengthened the provincial capital hospital, focused on the development of prefecture-level hospitals, and accelerated the layout of optometry outpatient clinics (clinics); Strengthen the provincial and regional management mechanism, promote the integrated management of prefectures and counties, explore the development of regional integration, integrate, share and optimize the allocation of regional resources, and promote the coordinated development of business capacity, efficiency and effectiveness. The headquarters of the company will continue to strengthen the construction of management, scientific research, training, service support system, etc., to further improve the guidance, support and control level of the headquarters for the operation of hospitals, comprehensively and continuously empower hospitals, and promote steady, high-quality and rapid development. During the reporting period, the company established the country's largest hierarchical diagnosis and treatment platform for difficult fundus diseases, which is composed of more than 300 fundus disease doctors across the country, covering 30 provinces and municipalities. This all-round, three-dimensional grid platform, with the help of network, mobile terminal and other technologies, will cover as much as possible, and will allow more fundus patients to relieve the crisis of blindness. 4. The science, education and research system is becoming more and more perfect, and the core competition is steadily improvingDuring the reporting period, the company's science, education and research system with "two institutes", "six institutes" and "two stations" as the core has become increasingly perfect, high-level scientific research achievements have been emerging, and the advantages of the platform have been further demonstrated. Prof. Tang Shibo, Prof. Chen Jiansu and their research team's paper "Study on the Construction of Highly Active Retinal Pigment Epithelial Cells (RPE) Using iPS Conditioned Medium and Femtosecond Corneal Lens" was published online in Acta Biomaterialia, an authoritative journal of global biomaterials. Professor Xu Heping and his research team's paper "Immune Regulation in the Aging Retina" was published online in Progress in Retinal and Eye Research, a top global journal in the field of ophthalmology, demonstrating the company's scientific research strength. During the reporting period, the company published a total of 128 papers in various journals, including 30 papers included in SCI/Medline, 64 papers included in Chinese core journals/Chinese scientific and technological paper statistical source journals, and 34 papers in other journals. The company's scientific research projects have been approved 42, 2 national projects, 19 provincial and ministerial projects, and 21 municipal projects. The company has organized experts to participate in international and domestic academic conferences, including the annual meeting of the American Association for the Study of Vision and Ophthalmology (ARVO-2019), the 2nd Westlake International Conference on Cataract and Refractive Surgery, the 34th Asia-Pacific Society of Ophthalmology, and the American Cataract and Refractive Annual Meeting (ASCRS2019). At the meeting, Aier experts participated in 51 speeches at international professional conferences, 2 hosts, and 50 exhibition boards and posters; 147 speakers, 11 moderators, and 362 posters or written exchanges participated in national professional conferences.The company's experts and well-known experts at home and abroad shared clinical experience, discussed the development of ophthalmology, demonstrated the company's scientific research and academic capabilities, and continuously enhanced the company's industry influence. 5. Continue to improve the medical management system and improve the level of medical quality and serviceDuring the reporting period, the company strengthened the construction of the medical system and system, standardized and optimized the business process, continued to improve the medical management system, and continuously improved the medical quality and service level. On the one hand, the company has formulated the "Aier Ophthalmology Vitrectomy Perioperative Drug Guidelines", "Emergency Response Plan for Cardiovascular and Cerebrovascular Accidents in High-risk Patients", "Preoperative Evaluation System for High-risk Patients" and other systems to strengthen the detailed management of diagnosis and treatment of high-risk patients. At the same time, the company implements provincial and regional management of medical quality, implements the performance appraisal of the dean, gives full play to the leading role of the dean, and focuses on medical quality; Establish quality control norms and quality control indicators for each academic group, gradually build a medical risk prevention and control system, and establish emergency plans and emergency consultation and disposal mechanisms for emergencies and mass incidents; On the other hand, focusing on "patient safety" to improve the service connotation, the company supervises the quality of medical services in hospitals and clinics on site, conducts key supervision and guidance on key departments and links, finds problems and rectifies them in a timely manner, and continuously improves medical services; At the same time, the training theme is formed based on the current situation, professional knowledge and management skills are preached in a timely manner, the risk prevention and control awareness of all medical and nursing technicians is improved, and the patients' medical experience and satisfaction are continuously improved. 6. Innovate talent training methods and strengthen the construction of talent teamsDuring the reporting period, the company innovated talent training methods, comprehensively promoted the implementation of ophthalmology high-level talent training projects such as "Photon Plan" and "Bocai Plan", and optimized the structure of medical talents. At the same time, the company set up Aier School of Management to cultivate high-end management talents in ophthalmology, and the construction of talent team was further strengthened. During the reporting period, the company launched the "Talent Plan", which is the first time that the company has released a training plan for young talents in the field of optometry and pediatric ophthalmology, which will help alleviate the shortage of high-level talents in this field in the future. In addition, the 2019 "Yuelu Phase I Advanced Hospital Management Training Course" of Aier School of Management was officially enrolled. At the same time, the third phase of the company's 2016 restricted stock incentive plan and the second phase of the reserved grant have been unlocked, and the long-term and sunny incentive mechanism has formed a good demonstration effect, and the gathering of outstanding talents has been accelerated, providing talent guarantee for the company's sustainable development. 7. Give full play to the advantages of professional ophthalmology institutions to help the national adolescent myopia prevention and controlDuring the reporting period, the company, as a professional ophthalmic medical institution, vigorously supported the national myopia prevention and control of children and adolescents in terms of professional talent allocation, technology and equipment introduction, capital investment, and department construction. The first is to vigorously introduce optometry professionals, strengthen talent training, and launch the talent plan to provide high-quality and high-level optometry professional services for children and adolescents. Article source: Internet